Clinical Trials Logo

Clinical Trial Summary

This will be a prospective, randomized, double-blind, placebo controlled study. Patients with established Type 1 diabetes will be eligible for entry into the study. Eligible patients will be screened and those who fulfill all inclusion/exclusion criteria will be admitted to the inpatient unit no fewer than 2 days and no more than 7 days after Screening. Patients will report to the inpatient unit at 6 a.m. and outfitted with a continuous glucose monitoring (CGM) device. Patients will be given standardized meals and snacks for the duration of their inpatient visit.


Clinical Trial Description

For the first 3 days, patients will be dosed with placebo 45 minutes prior to each of the day's 3 meals to establish baseline insulin requirements. Patients will be dosed with exogenous insulin according to their normal sliding scale and each patient's daily insulin requirement will be documented. The average daily insulin requirements during the 3 day run-in period will constitute the patient's baseline insulin level.

Following the 3 day run-in, the CGM device will be detached, its data download, and the patient refitted with the CGM with a fresh cannula for continued monitoring during the 7-day treatment period.

Patients will be randomized 2:1 to receive ORMD-0801 or placebo for the 7-day double-blind treatment period. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02094534
Study type Interventional
Source Oramed, Ltd.
Contact
Status Completed
Phase Phase 2
Start date March 2014
Completion date October 2014

See also
  Status Clinical Trial Phase
Recruiting NCT01508065 - Measuring and Monitoring Blood Glucose Levels Utilizing Non-invasive Blood Glucose Monitoring Device
Completed NCT01788033 - Effects of XOMA 052 on Insulin Production in Type 1 Diabetes Phase 2
Active, not recruiting NCT01271517 - Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis Phase 4
Recruiting NCT01800734 - Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study Phase 4
Recruiting NCT06088615 - Feasibility of Non-invasive Glucose Monitoring by Using Photothermal Deflectometry
Completed NCT02127047 - Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes Phase 2
Completed NCT01689090 - Diameter Changes of Retinal Vessels During Hypoxia N/A
Completed NCT00006505 - Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression Phase 2
Not yet recruiting NCT06217302 - Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease Phase 3
Recruiting NCT02750111 - Continuous Glucose Monitoring During Intecorse in Young Adults With Type 1 Diabetes N/A
Recruiting NCT02545062 - MoCa Test for the Early Detection of Mild Cognitive Impairment During Annual Assessment of Young Adults With Diabetes and in a Control Group Without Diabetes N/A
Completed NCT02146651 - A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes Phase 2
Completed NCT02538120 - Assessment of the Neurovascular Microcirculatory Response in Diabetes Type 1 Patients N/A
Completed NCT02403375 - Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes N/A
Terminated NCT00896610 - Natural History of Autoimmune Diabetes and Its Complications
Terminated NCT02701257 - The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas N/A
Completed NCT01334151 - Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes Phase 1
Active, not recruiting NCT02624804 - A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes Phase 1
Completed NCT02465411 - Long Term CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections N/A
Completed NCT02157155 - A Study of Intracellular Signaling in Muscle and Fat Cells During Ketosis N/A